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Fig. Direct cost and use of adjuncts vs primary patency. SFA, Superﬁcial
femoral artery.
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431 OAAA were linked to cost data at two centers. High-cost cases were
deﬁned as those in the upper quartile of cost for each procedure at each cen-
ter. VQI data elements were then examined for their relative risk of predict-
ing a high-cost outcome. Total cost of hospitalization for AAA repair was
the cost measure evaluated. Categoric variables were tested by c2 and
continuous variables by two-sample t-test.
Results: The cost of OAAA (mean, $28,183; range, $12,557-
$266,615) and EVAR (mean, $32,6546; range, $11,926-$60,894) at
center A were compared with OAAA (mean, $27,744; range, $7139-
$583,701) and EVAR (mean, $26,634; range, $5372-$302,111) at center
B. Factors linked to high cost are reported in the Table.
Conclusions: Markers of adverse intraoperative performance and
postoperative complications were better predictors of high-cost hospital-
izations than preoperative patient characteristics in both OAAA and
EVAR patients. Future efforts to optimize costs in all AAA repairs should
focus on improving intraoperative performance. This strategy differs
from other quality efforts where risk-adjusted models using preoperative
patient characteristics were developed to aid patient selection. The total
cost of EVAR (and potential applicability of this technology at a given
center) is signiﬁcantly affected by the structure of local stent graft
contracting.
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Objectives: One goal of the Patient Protection and Affordable Care
Act is to reduce hospital readmissions, with ﬁnancial penalties applied for
excessive rates of unplanned readmissions #30 days among Medicare ben-
eﬁciaries. Recent data indicate that as many as 24% of Medicare patients
require readmission after vascular surgery, although the rate of readmission
after limited digital amputations has not been speciﬁcally studied. The pre-
sent study was therefore undertaken to deﬁne the rate of unplanned read-
mission among patients after digital amputations and to identify the
factors associated with these readmissions to allow the clinician to imple-
ment strategies to reduce readmission rates in the future.
Methods: The electronic medical and billing records of all patients
undergoing minor amputations, deﬁned as toe or transmetatarsal (TMA)
amputations, using Current Procedural Terminology codes from January
2000 through July 2012 were retrospectively reviewed. Data were
collected for procedure, hospital-related variables, level of amputation,
length of stay, time to readmission, level of reamputation, and patient de-
mographics, including hypertension, diabetes, hyperlipidemia, smoking his-
tory, and history of myocardial infarction, congestive heart failure,
peripheral arterial disease, chronic obstructive pulmonary disease, , and ce-
rebrovascular accident.
Results: Minor amputations were performed in 775 patients
(62.2% male), including toe amputations in 564 (72.8%), TMAs in
151 (19.5%), and 60 (7.8%) undergoing Lisfranc or Chopart amputa-
tions. Readmission occurred in 105 patients (13.6%), including 29
(3.7%) #30 days, 29 (3.7%) from 30 to 60 days, and 47 (6.0%) at
>60 days after the index amputation. Multivariable analysis revealed
that elective admission (P < .001), peripheral arterial disease (P <
.001), history of myocardial infarction (P ¼ .0040), and chronic renal
insufﬁciency (P ¼ .017) were associated with readmission. The reasons
for readmission were infection (47.3%), ischemia (29.8%), nonhealing
wound (20.2%), and indeterminate (2.7%). Reamputation occurred in
99 (94.3%) of the readmitted patients, including limb amputation in
64 patients (65%), comprising below the knee in 58, through the knee
in 2, and above the knee in 4.
Conclusions: Readmission after minor amputation was associated
with limb amputation in most cases. Although efforts to reduce un-
planned hospital readmissions are laudable, payors must understand
that pressure to reduce readmission rates in the patient population
with extensive comorbidity may induce practitioners to undertake ampu-
tation at a higher level initially to minimize the risk of readmission for>Eastern Vascular Societyreamputation and associated ﬁnancial penalties and thus deprive the pa-
tient the chance for limb salvage.
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Objectives: Patients considered for endovascular treatment of superﬁ-
cial femoral artery (SFA) disease present with a wide array of lesion
complexity and treatment options. This study examined the cost drivers
of SFA stent treatment and their effect on outcome.
Methods: We retrospectively collected clinical and ﬁnancial data of pa-
tients undergoing SFA stenting to evaluate the relationship between direct
procedural cost and 1-year patency. Adjuncts to SFA stenting were deﬁned
as stent grafts, atherectomy, re-entry, and embolic protection devices.
Results: We studied 95 patients (62% male) who underwent SFA
stenting from January 2010 to February 2012. Patients were a mean age
of 71 years, 41% were diabetic, 46% had critical limb ischemia (CLI), and
24% had a TransAtlantic Inter-Society Consensus (TASC) C or D lesion.
Primary patency at 1 year was better in patients with claudication than
with CLI (91% vs 74%, P ¼ .06). Although the rate of adjunct use was
similar in patients with claudication and CLI (12%), more adjuncts were
used in patients with TASC C and D lesions (22% C and D, 8% A and B;
P ¼ .09). Mean direct costs for SFA stenting without adjunct use was
$2838 (95% conﬁdence interval, $2,586-$3,089), whereas adjunct use
increased mean costs to $7318 (95% conﬁdence interval, $4,817-$9,820;
P < .01). Multivariate regression showed that TASC C and D classiﬁcation
and adjunct use were associated with the highest tertile of costs (P < .05.
There was no association between cost and primary patency (Fig).
Conclusions: Adjunct devices are often necessary to achieve technical
success for treatment of TASC C and D SFA lesions. Their use is associated
with increased cost, yet has a minimal effect on midterm patency.Disclosures: K. Walker: Nothing to disclose; J. Columbo: Nothing to
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